Improved survival of type 2 diabetic patients on renal replacement therapy in Finland

Nephrology Dialysis Transplantation

Volumn 25, Issue 3, 2010, Pages 892-896

  Kervinen, Marjo ^a   Lehto, Seppo ^a   Ikäheimo, Risto ^b   Karhapää, Pauli ^a   Grönhagen Riska, Carola ^c,d   Finne, Patrik ^c,e  

^a KUOPIO UNIVERSITY HOSPITAL   (Finland)

^b OULU UNIVERSITY HOSPITAL   (Finland)

^c Finnish Registry for Kidney Diseases   (Finland)

^d HELSINKI UNIVERSITY CENTRAL HOSPITAL   (Finland)

^e UNIVERSITY OF TAMPERE   (Finland)

Author keywords

Diabetes mellitus; End stage renal disease; Survival

Indexed keywords

ALBUMIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL;

ADOLESCENT; ADULT; AGED; ALBUMIN BLOOD LEVEL; ARTICLE; CHILD; CHOLESTEROL BLOOD LEVEL; COHORT ANALYSIS; CONCENTRATION (PARAMETERS); DEATH; FEMALE; FINLAND; FOLLOW UP; GENDER; GROUPS BY AGE; HUMAN; INFANT; KIDNEY FAILURE; KIDNEY GRAFT; MAJOR CLINICAL STUDY; MALE; MORTALITY; NEWBORN; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REGISTER; RENAL REPLACEMENT THERAPY; SURVIVAL;

ADULT; AGED; AGED, 80 AND OVER; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DIABETIC NEPHROPATHIES; FEMALE; FINLAND; FOLLOW-UP STUDIES; HUMANS; KAPLAN-MEIERS ESTIMATE; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; RENAL REPLACEMENT THERAPY; RETROSPECTIVE STUDIES; RISK FACTORS; SURVIVAL RATE;

EID: 77649204660     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gfp555     Document Type: Article

References (25)

1. Finnish Registry for Kidney Diseases. Annual report 2005: Finland-Helsinki. Finnish Registry for Kidney Diseases, available from http:// www.musili.fi/smtr/english (2006).
2. Van Dijk PC, Jager KJ, Stengel B, et al. Renal replacement therapy for diabetic end-stage renal disease: data from 10 registries in Europe (1991-2000). Kidney Int 2005; 67: 1489-1499
3. McFarlane SI, Salifu MO, Makaryus J, et al. Anemia and cardiovascular disease in diabetic nephropathy. Curr Diab Rep 2006; 6: 213-218
4. McFarlane SI, Banerji M, Sowers JR. Insulin resistance and cardiovascular disease. J Clin Endocrinol Metab 2001; 86: 713-718
5. El-Atat FA, Stas SN, McFarlane SI, et al. The relationship between hyperinsulinemia, hypertension and progressive renal disease. J Am Soc Nephrol 2004; 15: 2816-2827
6. Foley RN, Culleton BF, Parfrey PS, et al. Cardiac disease in diabetic end-stage renal disease. Diabetologia 1997; 40: 1307-1312
7. Parfrey PS, Foley RN. The clinical epidemiology of cardiac disease in chronic renal failure. J Am Soc Nephrol 1999; 10: 1606-1615
8. Vlagopoulos PT, Sarnak MJ. Traditional and nontraditional cardiovascular risk factors in chronic kidney disease. Med Clin North Am 2005; 89: 587-611
9. Böger CA, Fischereder M, Deinzer M, et al. RANTES gene polymorphisms predict all-cause and cardiac mortality in type 2 diabetes mellitus hemodialysis patients. Atherosclerosis 2005; 183: 121-129
10. Rabbat CG, Thorpe KE, Russell JD, et al. Comparison of mortality risk for dialysis patients and cadaveric first renal transplant recipients in Ontario, Canada. J Am Soc Nephrol 2000; 11: 917-922
11. Finne P, Reunanen A, Stenman S, et al. Incidence of end-stage renal disease in patients with type 1 diabetes. JAMA 2005; 294: 1782-1787
12. Burnier M, Zanchi A. Blockade of the renin-angiotensin-aldosterone system: a key therapeutic strategy to reduce renal and cardiovascular events in patients with diabetes. J Hypertens 2006; 24: 11-25
13. Baber U, Toto RD, de Lemos JA. Statins and cardiovascular risk reduction in patients with chronic kidney disease and end-stage renal failure. Am Heart J 2007; 153: 471-477
14. Molitch ME. Management of dyslipidemias in patients with diabetes and chronic kidney disease. Clin J Am Soc Nephrol 2006; 1: 1090-1099
15. Gotz AK, Böger CA, Hirschmann C, et al. Effect of HMG-CoA-reductase inhibitors on survival in type 2 diabetes patients with end stage diabetic nephropathy. Eur J Med Res 2005; 10: 155-160
16. Wanner C, Krane V. Lessons learnt from the 4D trial. Nephrol Ther 2006; 2: 3-7
17. Spiegel DM. Anemia management in chronic kidney disease: what have we learned after 17years? Semin Dial 2006; 19: 269-272
18. Singh AK, Fishbane S. The optimal hemoglobin in dialysis patients-a critical review. Semin Dial 2008; 21: 1-6
19. Ronco C, Bowry S, Tetta C. Dialysis patients and cardiovascular problems: can technology help solve the complex equation? Blood Purif 2006; 24: 39-45
20. Qunibi WY. Reducing the burden of cardiovascular calcification in patients with chronic kidney disease. J Am Soc Nephrol 2005; 16 (Suppl 2): S95-S102
21. Okada T, Nakao T, Matsumoto H, et al. Association between markers of glycemic control, cardiovascular complications and survival in type 2 diabetic patients with end-stage renal disease. Intern Med 2007; 46: 807-814
22. Williams ME, Lacson E Jr, Teng M, et al. Hemodialyzed type I and type II diabetic patients in the US: characteristics, glycemic control, and survival. Kidney Int 2006; 70: 1503-1509
23. Sørensen VR, Mathiesen ER, Heaf J, et al. Improved survival rate in patients with diabetes and end-stage renal disease in Denmark. Dia-betologia 2007; 50: 922-929
24. Villar E, Chang SH, McDonald SP. Incidences, treatments, outcomes, and sex effect on survival in patients with end-stage renal disease by diabetes status in Australia and New Zealand (1991-2005). Diabetes Care 2007; 30: 3070-3076
25. Murtagh FE, Marsh JE, Donohoe P, et al. Dialysis or not? A comparative survival study of patients over 75years with chronic kidney disease stage 5. Nephrol Dial Transplant 2007; 22: 1955-1962